Authors | Title | Year | Source title | Cited by |
---|---|---|---|---|
Rawson et al. [42] | “Bacterial and Fungal Co-infection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing” | 2020 | Clinical Infectious Diseases | 716 |
Langford et al. [45] | “Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis” | 2021 | Clinical Microbiology and Infection | 217 |
Huttner et al. [44] | “COVID-19: don't neglect antimicrobial stewardship principles!” | 2020 | Clinical Microbiology and Infection | 177 |
Vaughn et al. [43] | “Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized with Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study” | 2021 | Clinical Infectious Diseases | 153 |
Rawson et al. [47] | “COVID-19 and the potential long-term impact on antimicrobial resistance” | 2020 | Journal of Antimicrobial Chemotherapy | 143 |
Clancy and Hong Nguyen [41] | “Coronavirus disease 2019, superinfections, and antimicrobial development: What can we expect?” | 2020 | Clinical Infectious Diseases | 141 |
Getahun et al. [40] | “Tackling antimicrobial resistance in the COVID-19 pandemic” | 2020 | Bulletin of the World Health Organization | 139 |
Imani et al. [38] | “Antimicrobial nanomaterials and coatings: Current mechanisms and future perspectives to control the spread of viruses including SARS-CoV-2” | 2020 | ACS Nano | 111 |
Hsu [39] | “How covid-19 is accelerating the threat of antimicrobial resistance” | 2020 | The BMJ | 110 |
Beovic et al. [46] | “Antibiotic use in patients with COVID-19: A 'snapshot' Infectious Diseases International Research Initiative (ID-IRI) survey” | 2020 | Journal of Antimicrobial Chemotherapy | 102 |